Publication

Het denosumab-dilemma: Na 5 jaar stoppen of doorgaan bij patiënten met osteoporose?

Wolffenbuttel, B. H. R., Abma, E. M. & Appelman-Dijkstra, N. M., 18-May-2018, In : Nederlands Tijdschrift voor Geneeskunde. 162, 21, 3 p., D2831.

Research output: Contribution to journalReview articleAcademicpeer-review

Copy link to clipboard

Documents

  • Het denosumab-dilemma

    Final publisher's version, 63 KB, PDF-document

Links

Denosumab is an effective treatment for osteoporosis. However, an increasing number of patients are developing so-called rebound vertebral fractures, because of a considerable increase of bone resorption after cessation of denosumab therapy. The prevalence of these new vertebral fractures is still unknown. In patients with high risk of new fractures, it is recommended to consider continuing denosumab treatment, or to switch to another antiresorptive medication such as bisphosphonates.

Translated title of the contributionThe denosumab dilemma: to be stopped after 5 years or to be continued in patients with osteoporosis?
Original languageDutch
Article numberD2831
Number of pages3
JournalNederlands Tijdschrift voor Geneeskunde
Volume162
Issue number21
Publication statusPublished - 18-May-2018

View graph of relations

ID: 77222117